Presenting at the Individualized Medicine Conference 2013, Elaine R. Mardis, Ph.D. discusses the therapeutic interpretations of next-generation sequencing. Dr. Mardis paints a picture of how these new sequencing options are bringing new interpretations and clinical applications for cancer patients.
Dr. Mardis is co-director of The Genome Institute at Washington University School of Medicine and a professor of genetics and molecular microbiology. As director of technology development, she helped create methods and automation pipelines for sequencing the human genome. She currently orchestrates the center's efforts to explore massively parallel sequencing technologies and transition them into production sequencing capabilities as well as new applications. Dr. Mardis has research interests in the application of DNA sequencing to characterize cancer genomes.